A retrospective study assessing the real-world outcome of patients with relapsed or refractory Small-cell Lung Cancer treated with checkpoint inhibitors in tertiary care centers across Germany
Latest Information Update: 18 Nov 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Nov 2021 New trial record
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress